Thermo Fisher Scientific Inc. (TMO)

DNB Asset Management AS cut its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 8.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 126,849 shares of the medical research company's stock after selling 12,465 shares during the quarter. DNB Asset

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may.

Citizens Business Bank raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 79.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,250 shares of the medical research company's stock after buying an

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com, with a replay accessible shortly after the presentation concludes. About Th.

Fairbanks Capital Management Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 77.8% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,248 shares of the medical research company's stock after purchasing an additional 1,421 shares during the quarter.

In this episode of The Morning Filter, co-hosts Dave Sekera and Susan Dziubinski unpack what the Supreme Court's ruling on the Trump Administration's emergency tariffs may mean for markets. They also discuss whether the AI-fueled stock market selloff has gone too far and where the opportunities may lie for investors today. They discuss if Nvidia's earnings report this week can lead to a recovery in AI-related stocks and if earnings releases from Salesforce CRM or Workday WDAY could lift their struggling stocks. Tune in to find out what to make of Walmart's WMT results, plus what Kraft Heinz's KHC breakup flip-flop and Elliot's investment in Norwegian Cruise Lines NCLH may mean for their stocks.

Bleakley Financial Group LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 10.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,425 shares of the medical research company's stock after acquiring an additional 1,500 shares during the

Factory Mutual Insurance Co. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 2.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 98,935 shares of the medical research company's stock after acquiring an additional 2,500 shares during the quarter. Factory

Fiera Capital Corp lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 3.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 151,374 shares of the medical research company's stock after selling 4,798 shares during the quarter. Fiera Capital

Insights into Glenview Capital Management's Fourth Quarter 2025 Moves Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for the fourth quarte

Crestwood Advisors Group LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 4.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 99,793 shares of the medical research company's stock after purchasing an additional 4,484

Fifth Third Bancorp increased its position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 327,665 shares of the medical research company's stock after buying an additional 6,440 shares during the

Assetmark Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 31.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,631 shares of the medical research company's stock after acquiring an additional 7,400 shares during

Cornerstone Investment Partners LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 85,342 shares of the medical research company's stock, valued at approximately $41,393,000. A number of other institutional

Caprock Group LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 8,500 shares of the medical research company's stock, valued at approximately $4,188,000. Other hedge funds and other institutional investors have